Antiphospholipid Antibodies and Fetal Growth Restriction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538134|
Recruitment Status : Unknown
Verified January 2015 by Osvaldo A. Reyes T., Saint Thomas Hospital, Panama.
Recruitment status was: Not yet recruiting
First Posted : February 23, 2012
Last Update Posted : January 5, 2015
|Condition or disease|
|Fetal Growth Restriction Antiphospholipid Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||90 participants|
|Observational Model:||Case Control|
|Official Title:||Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.|
|Study Start Date :||June 2015|
|Estimated Primary Completion Date :||February 2016|
|Estimated Study Completion Date :||March 2016|
Patients with ultrasonographic diagnosis of fetal growth restriction.
Patients with normal pregnancies at term.
- Lupus anticoagulant [ Time Frame: 8 months ]Number of cases positive for Lupus Anticoagulant.
- Anticardiolipin antibodies [ Time Frame: 10 months ]Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.
- B2 Glycoprotein I [ Time Frame: 10 months ]Number of cases with levels of B2 Glycoprotein I > 99%
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538134
|Saint Thomas Maternity Hospital|
|Principal Investigator:||Osvaldo Reyes, MD||Saint Thomas Hospital, Panama|